SAB Biotherapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	29.42	8.9	56.57	15.05	39.55	12.61
Short-Term Investments	81.46	11.86	-	-	-	-
Cash & Short-Term Investments	110.88	20.76	56.57	15.05	39.55	12.61
Cash Growth	264.73%	-63.30%	275.93%	-61.95%	213.59%	98.72%
Accounts Receivable	-	-	-	5.56	8.01	20.57
Other Receivables	0.56	0.05	-	-	-	-
Total Trade Receivables	0.56	0.05	-	5.56	8.01	20.57
Other Current Assets	1.84	2.98	2.34	1.49	2.64	1.28
Total Current Assets	113.28	23.79	58.91	22.1	50.19	34.46
Net Property, Plant & Equipment	19.44	19.92	24.68	28.34	30.95	22.08
Long-Term Investments	50.61	-	-	-	-	-
Other Long-Term Assets	0.12	0.48	0.35	0.47	-	-
Total Assets	183.45	44.2	83.94	50.9	81.14	56.54
Accounts Payable	2.95	1.69	0.95	3.68	4.46	7.38
Accrued Expenses	6.85	5.47	6.69	9.92	12.46	1.9
Short-Term Debt	-	0.28	1.05	0.77	-	-
Current Portion of Long-Term Debt	-	-	-	-	1.8	0.54
Current Portion of Leases	0.99	0.54	0.8	0.62	1.3	1.12
Unearned Revenue	-	-	1.32	-	0.1	0.1
Other Current Liabilities	-	-	-	-	6.34	0.02
Total Current Liabilities	10.79	7.98	10.81	14.99	26.46	11.06
Long-Term Debt	-	-	-	0.54	-	-
Long-Term Leases	5.2	3.86	4.05	3.99	1.65	2.37
Other Long-Term Liabilities	2.38	6.39	11.77	0.32	-	-
Total Long-Term Liabilities	7.58	10.25	15.83	4.85	1.65	2.37
Total Liabilities	18.37	18.23	26.64	19.85	28.11	13.43
Preferred Stock	0	0	0	-	-	-
Common Stock	0	0	0	0	-	-
Treasury Stock	-5.52	-5.52	-5.52	-5.52	-	-
Additional Paid-in Capital	264.55	155.79	152.86	84.45	-	-
Accumulated Other Comprehensive Income	0.07	-0.14	0.03	-	-	-
Retained Earnings	-94.03	-124.17	-90.06	-47.87	-	-
Total Common Shareholders' Equity	165.07	25.97	57.3	31.06	-	-
Shareholders' Equity	165.07	25.97	57.3	31.06	-	-
Total Liabilities & Equity	183.45	44.2	83.94	50.9	28.11	13.43
Total Debt	6.19	4.67	5.91	5.93	4.75	4.03
Net Cash (Debt)	104.69	16.09	50.66	9.12	34.79	8.58
Net Cash Growth	550.60%	-68.23%	455.59%	-73.79%	305.50%	11643.14%
Net Cash Per Share	3.96	1.74	9.18	2.10	12.73	3.18
Book Value	165.07	25.97	57.3	31.06	0	0
Book Value Per Share	6.24	2.80	10.38	7.14	-	-
Tangible Book Value	165.07	25.97	57.3	31.06	0	0
Tangible Book Value Per Share	6.24	2.80	10.38	7.14	-	-

Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q